Andreas Wallnöfer
Directeur/Bestuurslid bij Amal Therapeutics SA
Oorsprong van het eerstegraads netwerk van Andreas Wallnöfer
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
University of Basel
24
| College/University | Other Consumer Services | 24 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
15
| Subsidiary | Pharmaceuticals: Major | 15 |
International Institute for Management Development
12
| College/University | Other Consumer Services | 12 |
BioMedPartners AG
 BioMedPartners AG Investment ManagersFinance BioMedPartners AG (BMP), is an independant venture capital firm headquartered in Basel, Switzerland. BMP originated in 2002 as Seed Capital Advisors AG. The firm manages sector-focused venture capital funds including BioMedInvest, BioMedInvest II and BioMedCredit. They specialize in the biomedical sector.
9
| Private Company | Investment Managers | 9 |
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland.
8
| Holding Company | Pharmaceuticals: Major | 8 |
TOLREMO therapeutics AG
 TOLREMO therapeutics AG Miscellaneous Commercial ServicesCommercial Services TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Ventaleon GmbH
 Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany.
6
| Holding Company | Pharmaceuticals: Other | 6 |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.
4
| Subsidiary | Biotechnology | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Andreas Wallnöfer via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| University of St. Gallen | College/University | Masters Business Admin Masters Business Admin Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Graduate Degree | |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Chairman Director/Board Member Corporate Officer/Principal Founder Director of Finance/CFO | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Secretary Corporate Officer/Principal | |
Humedics GmbH
 Humedics GmbH Packaged SoftwareTechnology Services Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany. | Packaged Software | Director/Board Member Director/Board Member Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Aravis AG
 Aravis AG Investment ManagersFinance Aravis AG (Aravis) is an independent venture capital firm, founded in 2001 by Jean-Philippe Tripet and headquartered in Muttenz, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| University of Zurich | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Compliance Officer Comptroller/Controller/Auditor | |
Thommen Medical AG
 Thommen Medical AG Medical SpecialtiesHealth Technology Thommen Medical AG develops and manufactures dental implant systems. It offers include implants, prosthetics, digital solutions, and case planning. The company Grenchen, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member Chairman | |
| UBS | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal Comptroller/Controller/Auditor | |
Basel Chamber of Commerce
 Basel Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services The Basel Chamber of Commerce is an organization that advocates for the interests of the industry and promotes the region as the most important logistics hub in Switzerland. The non-profit company is based in Basel, Switzerland. The company also has a Swiss School for International Business. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| SANTHERA PHARMACEUTICALS HOLDING AG | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Biotechnology | Director/Board Member Director/Board Member | |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Pharmaceuticals: Major | Director/Board Member Chairman | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Director/Board Member | |
Aleva Neurotherapeutics SA
 Aleva Neurotherapeutics SA Electronic Equipment/InstrumentsElectronic Technology Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland. | Electronic Equipment/Instruments | Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Medical Specialties | Director/Board Member Director/Board Member | |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AYOXXA Biosystems GmbH
 AYOXXA Biosystems GmbH BiotechnologyHealth Technology AYOXXA Biosystems GmbH operates as a biotechnology firm. Its lunaris technology is the optimal analysis platform for the pre-clinical and clinical development work. The firm offers In-situ encoded bead array, a multiplexed protein analysis platform that allows users to measure proteins and biomolecular analytes. The company was founded by Dieter Trau and Andreas Schmidt in 2010 and is headquartered in Cologne, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
| IMMUNE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| FLEXION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| VECTURA GROUP | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Inotrem SA
 Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Investment Managers | Corporate Officer/Principal Founder | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Vischer AG
 Vischer AG Miscellaneous Commercial ServicesCommercial Services Vischer AG provides legal advisory services. The private company is based in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| PAREXEL INTERNATIONAL CORPORATION | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| London Business School | College/University | Masters Business Admin Masters Business Admin | |
Bellevue Asset Management (Venture Capital)
 Bellevue Asset Management (Venture Capital) Investment ManagersFinance Bellevue Asset Management (Venture Capital) is the venture capital arm of Bellevue Asset Management AG, a subsidiary of Bellevue Group AG (SW: BBN) headquartered in Zurich, Switzerland. The firm was founded in 1993. | Investment Managers | Private Equity Investor Private Equity Investor | |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Founder Private Equity Investor | |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: OtherHealth Technology PIQUR Therapeutics AG engages in development of anti-cancer drugs based on the inhibition. Its products include PQR309, PQR620 and PQR5xx. The company was founded by Bernd Giese, Vladimir Cmiljanovic, Andreas Emmenegger, Ralf Rosenow and Matthias Wymann in August 2011 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Other | Founder Director/Board Member | |
| University of Lausanne | College/University | Graduate Degree Undergraduate Degree | |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| MOLECULAR PARTNERS AG | Biotechnology | Director of Finance/CFO Director/Board Member | |
Roche Glycart AG
 Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| Università degli Studi di Napoli Federico II | College/University | Doctorate Degree Doctorate Degree | |
ProteoMediX AG
 ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Biotechnology | Chief Executive Officer |
Statistieken
Internationaal
| Zwitserland | 29 |
| Duitsland | 5 |
| Verenigde Staten | 5 |
| Nederland | 5 |
| Frankrijk | 4 |
Sectoraal
| Health Technology | 27 |
| Consumer Services | 9 |
| Finance | 8 |
| Commercial Services | 7 |
| Technology Services | 2 |
Operationeel
| Director/Board Member | 376 |
| Corporate Officer/Principal | 152 |
| Chairman | 68 |
| Independent Dir/Board Member | 50 |
| Doctorate Degree | 46 |
Sterkste connecties
| Insiders | |
|---|---|
| Jürgen Eckhardt | 34 |
| Hugo Slootweg | 34 |
| Simon Jules Nebel | 23 |
| Rafaèle Elisabeth Tordjman | 23 |
| Jason Robert Dinges | 22 |
| Karin Hehenberger | 21 |
| Zafrira Avnur | 20 |
| Martin C. Münchbach | 20 |
| Gert Thönen | 19 |
| Matthias Alder | 18 |
| Matti Juhani Alahuhta | 18 |
| Dorothée Anna Deuring | 17 |
| Christian Schneider | 17 |
| Beat Oberlin | 17 |
| Arnd Kaltofen-Ehmann | 16 |
- Beurs
- Insiders
- Andreas Wallnöfer
- Bedrijfsconnecties
